Riassunto
With the advent of analytical techniques and capabilities to measure particle sizes in nanometer ranges, there has been tremendous interest in the use of nanoparticles for more efficient methods of drug delivery. Nanoparticulate Drug Delivery Systems addresses the scientific methodologies, formulation, processing, applications, recent trends, and emerging technologies in the research of nanoparticulate drug delivery systems (NPDDS). It extensively covers applications of NPDDS― including lipid nanoparticles for dermal applications; nanocarriers for the treatment of restenosis; and for ocular, central nervous system, and gastrointestinal applications. It also explores its use as an adjuvant for vaccine development.
Supplying insight from international experts, this guide
- Discusses formulation for poorly soluble drugs
- Presents biological requirements for nanotherapeutic applications
- Demonstrates the role of nanobiotechnology in the development of nanomedicine
- Documents recent advances in nanoparticulate technology―including electrospining, formation of microcrystals, and production of liquid crystalline phases
- Examines the technology of metallic nanoparticles
Informazioni sull?autore
UCB Pharma, Inc., Rochester, New York. He is responsible for developing IEDS technology, which is used to formulate extended release suspensions. During his fifteen-year career, he has led the development of several marketed extended release products and has published numerous scientific articles in the field of oral and transdermal drug delivery systems. Dr. Thassu holds several US and European patents and received the M. Pharm. degree in pharmaceutics (1986) from Saugor University, India, the Ph.D. degree in pharmaceutical sciences (1991) from the University of Cincinnati, Ohio, and the MBA degree (2007) from Cornell University, Ithaca, New York. MICHEL DELEERS is Vice President, Global Pharmaceutical Technology and Analytical Development and Clinical Supplies for UCB Pharma, Chemin du Foriest, Braine l’Alleud, Belgium, responsible for developing products with new drug delivery systems, new nano and microparticulate systems, and alternative routes of adminstration for insoluble and biological drugs. He received the Ph.D. degree in chemical sciences (1978) and the D.Sc. degree (1986) from the Université Libre de Bruxelles, Belgium. A member of the Royal Chemical Society of Belgium, the International Pharmaceutical Federation (FIP), and the American Association of Pharmaceutical Scientists (AAPS), Dr. Deleers has published more than 125 scientific articles and has obtained 20 patents. YASHWANT PATHAK is currently Director, Research and Development for PharmaFab, Grand Prairie, Texas, a company providing contract research services for specialized drug delivery systems. The author of over 100 research publications, including several papers on sub-micronized emulsions and PLA: PLGA nano-particles, he began his career as a Lecturer in pharmaceutics at Delhi University, New Delhi, India. Dr. Pathak received the Ph.D. degree from Nagpur University, India and was awarded a fellowship from the American Heart Association to complete research on cardiovascular drug delivery systems.
Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.
